Currently, there is no effective pharmacological treatment for non-functioning pituitary adenoma, including gonadotroph adenoma (GPA). Recent findings showed that an alternative pharmacological treatment targeted at somatostatin receptor 3 may be promising, which required accurate diagnosis of GPA before surgery. This study aimed to evaluate the utility of magnetic resonance fingerprinting (MRF) in the pre-surgical differentiation of GPA from non-functioning, non-gonadotropin adenoma (NGPA). The results showed that GPAs have significantly higher T1 and T2 values in the solid tumor than NGPA, suggesting that MRF may have potential for diagnosing GPA and benefit its treatment plan.
This abstract and the presentation materials are available to members only; a login is required.